DK2119450T3 - Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener - Google Patents

Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener

Info

Publication number
DK2119450T3
DK2119450T3 DK09169276.4T DK09169276T DK2119450T3 DK 2119450 T3 DK2119450 T3 DK 2119450T3 DK 09169276 T DK09169276 T DK 09169276T DK 2119450 T3 DK2119450 T3 DK 2119450T3
Authority
DK
Denmark
Prior art keywords
induction
pancreatic islet
beta cell
islet beta
mucosal tolerance
Prior art date
Application number
DK09169276.4T
Other languages
English (en)
Inventor
Pieter Rottiers
Veerle Snoeck
Original Assignee
Actogenix Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actogenix Nv filed Critical Actogenix Nv
Application granted granted Critical
Publication of DK2119450T3 publication Critical patent/DK2119450T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/50—Feeding-stuffs specially adapted for particular animals for rodents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
DK09169276.4T 2005-11-29 2006-11-29 Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener DK2119450T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05111467 2005-11-29
EP06830192.8A EP1957100B1 (en) 2005-11-29 2006-11-29 Induction of mucosal tolerance to antigens

Publications (1)

Publication Number Publication Date
DK2119450T3 true DK2119450T3 (da) 2013-05-06

Family

ID=37889980

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09169276.4T DK2119450T3 (da) 2005-11-29 2006-11-29 Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener

Country Status (13)

Country Link
US (5) US8748126B2 (da)
EP (3) EP3097924B1 (da)
JP (2) JP5410759B2 (da)
CN (1) CN101316611B (da)
AU (1) AU2006319216B2 (da)
BR (1) BRPI0619206A2 (da)
CA (1) CA2631598C (da)
DK (1) DK2119450T3 (da)
ES (2) ES2596855T3 (da)
HK (1) HK1231371A1 (da)
PT (1) PT2119450E (da)
RU (1) RU2420569C2 (da)
WO (1) WO2007063075A1 (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
DK2119450T3 (da) 2005-11-29 2013-05-06 Actogenix Nv Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener
AU2006326405B2 (en) 2005-12-13 2013-10-31 President And Fellows Of Harvard College Scaffolds for cell transplantation
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
JP2010513245A (ja) * 2006-12-14 2010-04-30 アクトジェニックス・エヌブイ 免疫調節を誘起するための結合分子の送達
ES2492468T3 (es) 2007-01-25 2014-09-09 Actogenix N.V. Tratamiento de enfermedad inmunitaria por administración a través de la mucosa de antígenos usando Lactobacillus genéticamente modificado
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
FI20075539L (fi) * 2007-07-12 2009-01-13 Valio Oy Maitohappobakteerit, joilla on proinflammatorisia ominaisuuksia
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
CA2715460C (en) 2008-02-13 2020-02-18 President And Fellows Of Harvard College Continuous cell programming devices
EP2331124A1 (en) 2008-08-15 2011-06-15 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
EP2153841B2 (en) 2008-08-15 2015-11-11 Circassia Limited Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy
WO2010056143A1 (en) * 2008-11-13 2010-05-20 Instituto De Medicina Molecular The use of adjuvant to facilitate the induction of immune tolerance
EP2393830B8 (en) 2009-02-05 2015-03-18 Circassia Limited Grass peptides for vaccine
US10617640B2 (en) 2009-07-07 2020-04-14 The Research Foundation For The State University Of New York Phosphoserine containing compositions for immune tolerance induction
EP3058953A1 (en) * 2009-07-07 2016-08-24 The Research Foundation Of State University Of New York Lipidic compositions for induction of immune tolerance
CA2768552A1 (en) * 2009-07-31 2011-02-03 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
US20110081320A1 (en) * 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
US20130058898A1 (en) * 2010-03-10 2013-03-07 Kaneka Corporation Lactic acid bacterium-containing preparation
WO2011150235A1 (en) * 2010-05-27 2011-12-01 Allertein Therapeutics, Llc Methods and reagents for treating autoimmune disorders and/or graft rejection
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
PT2624873T (pt) 2010-10-06 2020-03-04 Harvard College Hidrogéis injectáveis formadores de poros para terapias celulares à base de materiais
ES2685327T3 (es) 2011-04-28 2018-10-08 President And Fellows Of Harvard College Armazones tridimensionales macroscópicos preformados inyectables para administración mínimamente invasiva
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
EP2714073B1 (en) 2011-06-03 2021-03-10 President and Fellows of Harvard College In situ antigen-generating cancer vaccine
EP2758512B1 (en) 2011-09-23 2018-05-09 Intrexon Actobiotics NV Modified gram positive bacteria and uses thereof
CN103917639B (zh) 2011-09-23 2017-09-26 英特瑞克斯顿阿克图比奥帝克斯有限公司 经修饰的革兰氏阳性细菌及其用途
EP2726089A2 (en) * 2012-02-08 2014-05-07 Premune AB Prevention of inflammatory disorders in domestic non-human mammals
HUE047973T2 (hu) 2012-04-16 2020-05-28 Harvard College Mezoporózus szilíciumdioxid készítmények immunválaszok modulálására
MX370265B (es) * 2012-05-25 2019-12-09 Cellectis Métodos para manipular por ingeniería genética célula t alogénica y resistente a inmunosupresores para inmunoterapia.
JP6219728B2 (ja) * 2014-01-15 2017-10-25 キッコーマン株式会社 Ｆｏｘｐ３陽性制御性Ｔ細胞とＩＦＮ−γ産生ＩＬ−１０産生Ｔ細胞誘導を指標とした、経口免疫寛容物質スクリーニング方法及び経口免疫寛容増強組成物
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
AU2015233084B2 (en) * 2014-02-21 2020-12-17 Anokion Sa Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
CN107073090A (zh) 2014-04-30 2017-08-18 哈佛学院董事会 结合的疫苗装置和杀死癌细胞的方法
EP2989904A1 (en) * 2014-07-29 2016-03-02 Heinrich-Heine-Universität Induction of immunological tolerance using yeast
KR101662898B1 (ko) * 2014-09-02 2016-10-06 서울대학교산학협력단 점막점착성 고분자 및 이의 용도
JP6581208B2 (ja) 2014-12-23 2019-09-25 イリヤ ファーマ エービー 創傷治癒の方法
WO2016115253A1 (en) 2015-01-14 2016-07-21 The Regents Of The University Ofcolordo, A Body Corporate Insulin mimotopes and methods of using the same
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
CN107708756A (zh) 2015-04-10 2018-02-16 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
EP3081227A1 (en) * 2015-04-15 2016-10-19 Institut National De La Recherche Agronomique Lactococcus lactis producing tslp or il-25 and their uses as probiotics and therapeutics
WO2017062175A1 (en) * 2015-10-06 2017-04-13 Albert Einstein College Of Medicine, Inc. Microbial hyperswarmers and uses thereof
JP7138864B2 (ja) 2016-02-06 2022-09-20 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫を再構成するための造血ニッチの再現
CN115404196A (zh) 2016-07-13 2022-11-29 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
RU2768027C2 (ru) * 2016-09-02 2022-03-23 Интрексон Актобиотикс Н.В. Генетически модифицированные бактерии, стабильно экспрессирующие ил-10 и инсулин
KR102469701B1 (ko) 2016-09-13 2022-11-22 인트랙슨 액토바이오틱스 엔.브이. 점막부착성 미생물
CN108114272A (zh) * 2016-11-28 2018-06-05 上海市第五人民医院 一种构建哮喘免疫耐受模型的方法
AU2018338786A1 (en) * 2017-09-29 2020-04-16 Nantcell, Inc. Antigenic proteins and methods therefor
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
JP2020000033A (ja) * 2018-06-26 2020-01-09 国立大学法人広島大学 経口免疫寛容誘導剤、これを含有する食品および医薬品、ならびに加工食品の製造方法
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CN110408579A (zh) * 2019-06-03 2019-11-05 东北农业大学 牛白细胞介素-2重组乳酸菌及其应用
US20220340621A1 (en) 2019-09-27 2022-10-27 Intrexon Actobiotics Nv D/B/A Precigen Actobio Treatment of celiac disease
BR112022025381A2 (pt) 2020-06-11 2023-01-24 Provention Bio Inc Métodos e composições para prevenir diabetes tipo 1

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100495A (en) 1975-11-27 1978-07-11 Cselt - Centro Studi E Laboratori Telecomunicazioni Adaptive method of and means for recovering digital signals
US4190495A (en) 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
US4874702A (en) 1980-09-08 1989-10-17 Biogen, Inc. Vectors and methods for making such vectors and for expressive cloned genes
US4888170A (en) 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
US5417986A (en) 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5032510A (en) 1984-09-26 1991-07-16 Eli Lilly And Company Method for expression and secretion in bacillus
IL76422A0 (en) 1984-09-26 1986-01-31 Lilly Co Eli Method for expression and secretion in bacillus
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US5591632A (en) 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
EP0347425B1 (en) 1987-03-02 1995-12-27 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine
US5330753A (en) 1987-04-29 1994-07-19 President And Fellows Of Harvard College Cholera vaccines
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US5972685A (en) 1988-07-21 1999-10-26 Iowa State University Research Foundation, Inc. Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration
IE892131A1 (en) 1989-06-30 1991-01-02 Univ Cork Marker genes for genetic manipulation
US5149532A (en) 1989-11-01 1992-09-22 Cedars Sinai Medical Center Method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms
DE4006521A1 (de) 1990-03-02 1991-09-05 Bayer Ag Zuckerhaltige polymere zur umhuellung und einbettung von arzneistoffen
GB9006400D0 (en) 1990-03-22 1990-05-23 Ciba Geigy Ag Bacterial vectors
IL99097A0 (en) 1990-09-05 1992-07-15 Akzo Nv Haemophilus paragallinarum vaccine
AU664360B2 (en) 1991-03-05 1995-11-16 Wellcome Foundation Limited, The Expression of recombinant proteins in attenuated bacteria
DK0607278T3 (da) 1991-10-07 2002-06-17 Brigham & Womens Hospital Fremgangsmåde til forstærkning af tarmabsorption
IL103530A0 (en) 1991-10-25 1993-03-15 Duphar Int Res Treponema hyodysenteriae vaccine
US6221648B1 (en) 1992-02-27 2001-04-24 Microdial Technics Ltd. Heterologous gene expression in lactococcus, and the expression products therefrom
US5455034A (en) 1992-06-26 1995-10-03 Kansas State University Research Foundation Fusobacterium necrophorum leukotoxoid vaccine
DE4231764A1 (de) 1992-09-23 1994-03-24 Inst Pflanzengenetik & Kultur Verfahren zur chromosomalen Integration eines Produkt-Gens
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5691185A (en) 1993-10-08 1997-11-25 Chr. Hansen A/S Lactic acid bacterial suppressor mutants and their use as selective markers and as means of containment in lactic acid bacteria
CA2173751A1 (en) 1993-10-13 1995-04-20 Sýren Molin Recombinant staphylococcal nucleases and their use in limiting the survival of genetically engineered microorganisms
IT1270123B (it) 1994-10-05 1997-04-28 Dompe Spa Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
US5733540A (en) 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
AU2149495A (en) 1995-04-11 1996-10-30 Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno Method for the construction of vectors for lactic acid bacte ria like lactobacillus such that the bacteria can efficientl y express, secrete and display proteins at the surface
US5753622A (en) 1995-05-10 1998-05-19 University Technologies International, Inc. Use of epidermal growth factor as a gastrointestinal therapeutic agent
ATE312934T1 (de) 1995-06-07 2005-12-15 Univ Washington Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
GB9518323D0 (en) 1995-09-07 1995-11-08 Steidler Lothar Materials and methods relating to the attachment and display of substances on cell surfaces
GB9521568D0 (en) 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
JP2000516911A (ja) * 1996-03-28 2000-12-19 ホワイトヘッド インスティテュート フォー バイオメディカル リサーチ オプソニン強化細胞、および抗原に対する免疫応答を調節する方法
JP2000508645A (ja) 1996-04-12 2000-07-11 ペプテック リミテッド ポリ不飽和脂肪酸を使用する免疫病の治療方法
ATE331798T1 (de) 1996-04-19 2006-07-15 Jackson H M Found Military Med Verfahren zur anregung einer immunantwort durch verabreichung von nutzorganismen, die intimin allein oder als fusionsprotein mit einem oder mehreren anderen antigenen exprimieren
US5972887A (en) 1996-09-19 1999-10-26 The Nemours Foundation Treatment of intestinal epithelial cell malfunctions with Hepatocyte Growth Factor
US5723245A (en) 1996-10-09 1998-03-03 Xerox Corporation Colored toner and developer compositions and process for enlarged color gamut
US7361331B2 (en) * 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
GB9700939D0 (en) 1997-01-17 1997-03-05 Microbial Technics Limited Therapy
US6685943B1 (en) 1997-01-21 2004-02-03 The Texas A&M University System Fibronectin binding protein compositions and methods of use
DK0892054T3 (da) 1997-06-20 2007-04-02 Intervet Int Bv Clostridium perfringens-vaccine
US6100388A (en) 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
EP1075512B1 (en) 1998-05-07 2010-04-14 Universite Libre De Bruxelles Cytotoxin-based biological containment
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
AU757343B2 (en) 1998-09-28 2003-02-20 Capsugel Belgium Nv Enteric and colonic delivery using HPMC capsules
AU1071200A (en) 1998-10-19 2000-05-08 Biotech Australia Pty Limited Systems for oral delivery
DE69914932T2 (de) 1998-10-20 2004-12-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
US7220418B1 (en) 1999-07-05 2007-05-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Delivery of trefoil peptides
ATE449861T1 (de) 2000-10-20 2009-12-15 Bioneer As Verfahren zur fermentativen herstellung von heterologen genprodukten in milchsäurebakterien
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
DE60212825T2 (de) 2001-05-03 2007-01-11 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Selbsterhaltender lactococcus stamm
NO318426B1 (no) 2001-10-02 2005-04-18 Neurozym Biotech As Et materiale for a senke konsentrasjonen av patogene tarmpeptider
EP1319410A1 (en) 2001-12-11 2003-06-18 Société des Produits Nestlé S.A. Use of micro-organisms for a directed delivery of substances to specific parts of the gut
US20040043003A1 (en) 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
DE10208653A1 (de) * 2002-02-28 2003-09-18 Medinnova Ges Med Innovationen Mikroorganismus als Träger von Nukleotidsequenzen kodierend für Zellantigene zur Behandlung von Tumoren
US7425449B2 (en) 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
AU2003234634A1 (en) 2002-05-14 2003-12-02 Felix Hausch Drug therapy for celiac sprue
EP1364586A1 (en) 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
JP2005529622A (ja) 2002-06-19 2005-10-06 ヴェーイーベー・ヴェーゼットウェー 腸吸収を促進するための方法および手段
AU2003298291A1 (en) 2002-11-15 2004-06-15 Universiteit Gent Self-containing lactobacillus strain
DK1563300T3 (da) 2002-11-20 2012-07-23 Univ Leland Stanford Junior Diagnostisk fremgangsmåde til cøliaki
JP4589618B2 (ja) 2003-11-28 2010-12-01 独立行政法人農業生物資源研究所 免疫調節性機能を誘導する乳酸菌類とその成分
JP2007520566A (ja) * 2004-02-04 2007-07-26 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 自己免疫治療のための抗ｃｄ３及び抗原特異的免疫療法
CN1695469A (zh) 2005-05-17 2005-11-16 田星 一种风味益生发酵乳及其制作方法
DK2119450T3 (da) * 2005-11-29 2013-05-06 Actogenix Nv Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener
ES2492468T3 (es) 2007-01-25 2014-09-09 Actogenix N.V. Tratamiento de enfermedad inmunitaria por administración a través de la mucosa de antígenos usando Lactobacillus genéticamente modificado

Also Published As

Publication number Publication date
EP2119450A3 (en) 2010-06-30
US9539291B2 (en) 2017-01-10
ES2596855T3 (es) 2017-01-12
US20140322266A1 (en) 2014-10-30
EP1957100B1 (en) 2016-07-13
HK1231371A1 (zh) 2017-12-22
JP2013189446A (ja) 2013-09-26
AU2006319216A1 (en) 2007-06-07
EP3097924B1 (en) 2020-01-08
CN101316611B (zh) 2017-05-03
EP3097924A1 (en) 2016-11-30
JP2009521406A (ja) 2009-06-04
AU2006319216B2 (en) 2012-09-13
US10195269B2 (en) 2019-02-05
CA2631598C (en) 2017-06-27
PT2119450E (pt) 2013-04-26
JP5410759B2 (ja) 2014-02-05
US20100172920A1 (en) 2010-07-08
CN101316611A (zh) 2008-12-03
CA2631598A1 (en) 2007-06-07
EP1957100A1 (en) 2008-08-20
RU2008126198A (ru) 2010-01-10
US20170100475A1 (en) 2017-04-13
US20090148389A1 (en) 2009-06-11
WO2007063075A1 (en) 2007-06-07
RU2420569C2 (ru) 2011-06-10
US8398995B2 (en) 2013-03-19
EP2119450A2 (en) 2009-11-18
ES2405552T3 (es) 2013-05-31
US20140322230A1 (en) 2014-10-30
US9526750B2 (en) 2016-12-27
US8748126B2 (en) 2014-06-10
EP2119450B1 (en) 2013-02-13
BRPI0619206A2 (pt) 2011-09-20

Similar Documents

Publication Publication Date Title
DK2119450T3 (da) Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener
DK1989008T3 (da) Fremstilling af sekundære aggregater
DK2300560T3 (da) Termisk behandling af biomasse
DK3287525T3 (da) RNA-præparater omfattende oprenset modificeret RNA til omprogrammering af celler
DK2620493T3 (da) Mesenkymale stamceller til behandling af CNS-sygdomme
DK2419144T3 (da) Sammensætning til levering af genetisk materiale
DK1896572T3 (da) Fremgangsmåde til fremstilling af organotypiske cellekulturer
DK2114886T3 (da) Fremgangsmåde til fremstilling af visse substituerede sulfiliminer
DK1877568T4 (da) Hydrolysering af arabinoxylan
FI20095427A (fi) Menetelmä triglyseridien konvertoimiseksi biopolttoaineiksi
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK1879981T3 (da) Fremgangsmåde til omdannelse af organisk materiale til kul-brintebrændstoffer
DK2219469T3 (da) Modificering af enzymatisk disponerede proteiner
DK3241843T3 (da) Opløselighedsoptimering af immunbindere
DK2396089T3 (da) Fremgangsmåde til omdannelse af organisk materiale til methanrig brændgas
DK2348064T3 (da) Fremgangsmåde til fremstilling af polyalkylenglycolderivater
DK3219804T3 (da) Afgiftning af forbehandlede lignocelluloseholdige materialer
DK2111555T3 (da) Diagnosticering af præeklampsi
DK2180787T3 (da) Nitrooliesyremodulering af type ii-diabetes
DK1884507T3 (da) Fremgangsmåde til fremstilling af glycerol
DK2011858T3 (da) Et galderesistent bacillus-præparat med høje niveauer af fytase-udskillelse
DK2178900T3 (da) Oprensning af pegylerede polypeptider
DK3037538T3 (da) Fremgangsmåder og sammensætninger til specifik inhibering af beta-catenin ved hjælp af dobbeltstrenget rna
DK2081675T3 (da) Syntese af biodiesel
DK2342346T3 (da) Thermotoga til behandling af biomasse